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Abstract:
The present study was conducted to determine if the ketogenic diet altered basal levels of
monoamine neurotransmitters in mice. The catecholamines dopamine (DA) and norephinephrine
(NE) and the indolamine serotonin (5HT) were quantified postmortem in six different brain
regions of adult mice fed a ketogenic diet for 3 weeks. The dopamine metabolites 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and the serotonin
metabolite 5-hydroxyindole acetic acid (5HIAA) were also measured. Tissue punches were
collected bilaterally from the motor cortex, somatosensory cortex, nucleus accumbens, anterior
caudate-putamen, posterior caudate-putamen and the midbrain. Dopaminergic activity, as
measured by the dopamine metabolites to dopamine content ratio – ([DOPAC] + [HVA])/[DA] was significantly increased in the motor and somatosensory cortex regions of mice fed the
ketogenic diet when compared to those same areas in brains of mice fed a normal diet. These
results indicate that the ketogenic diet alters the activity of the meso-cortical dopaminergic
system, which may contribute to the diet's therapeutic effect in reducing epileptic seizure
activity.
Key words: Ketogenic diet, monoamines, dopamine, serotonin, HPLC, tissue punch
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Introduction:
Epilepsy is a predominant neurological disorder which induces recurrent episodes of
convulsive seizures, loss of consciousness, sensory disturbances and abnormal behavior. The
ketogenic diet is a high fat, low protein and carbohydrate diet utilized as a non-pharmacological
therapeutic alternative for individuals suffering from drug resistant epilepsy [1,2]. While the
exact neuronal mechanism by which the ketogenic diet induces its therapeutic effect remains
unclear, recent research suggests an involvement of monoamine neurotransmitters [3,4,5],
adenosine [6,7,8] and glutamatergic transmitter systems [9,10] within the central nervous system.
In addition to affecting numerous chemical systems in the CNS, the ketogenic diet has
been reported to selectively impact specific brain structures. Zarnowski et al. [11] have shown
that the levels of the tryptophan metabolite kynurenic acid were increased in the hippocampus
and striatum, but not the cortex of female rats fed a ketogenic diet for 21 days. Alternatively,
Cantello et al. [12] reported that the ketogenic diet increased inhibition of neuronal activity in the
cerebral cortex of non-epileptic humans. To evaluate if the ketogenic diet altered basal
monoamine neurotransmitter content in a region specific manner, the present study measured the
concentrations of norepinephrine (NE), dopamine (DA), serotonin (5-HT), 3,4dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindole acetic acid (5HIAA) and homovanillic
acid (HVA) in the brains of mice maintained on a three week ketogenic diet. The endogenous
levels of these neuroactive compounds were determined in the motor cortex (MC),
somatosensory cortex (SC), nucleus accumbens (NA), anterior and posterior caudate putamen
(ACPu and PCPu, respectively) and the midbrain (MB) using micropunch sampling coupled with
separation and quantification by high performance liquid chromatography with electrochemical
and UV detection.

Material and Methods:
All animal care and use and surgical procedures were approved by the Institutional
Animal Care and Use Committee of Trinity College and are in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals. Discrete brain region
tissue collection and biogenic amine content determination was conducted as previously
described [13,14]. Briefly, 8 week old mice were placed on either a three week chronic
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ketogenic diet (#F3666 Bioserve, Frenchtown NJ USA) or control diet (LabDiet 5001,
Pharmaserv, Framingham, MA USA). Changes in blood glucose and β-hydroxybutyrate levels
between control and KD mice were observed (140.5±22.2 mg/dL v. 78.8±18.8 mg/dL and
0.26±0.1mM v. 2.8±1.4mM, respectively). Naïve mice were decapitated and whole brains were
quickly dissected and collected into -20°C isopentane. Time from decapitation to immersion in
isopentane was 30-40 seconds. To ensure similar dissection technique for all animals and
treatment groups, all dissections were performed by the same experimenter. After freezing,
brains were removed from isopentane and stored at -80°C until punch collection. Bilateral tissue
punches (1 mm thick, 1 mm diameter) were acquired from the motor cortex, somatosensory
cortex, nucleus accumbens, anterior caudate, posterior caudate, and the midbrain. Specific brain
sites were identified using a standard mouse atlas [15]. The samples were homogenized in 400
µL of ethanol containing 10 µL of anti-oxidant solution [dihydroxybenzyl amine (DHBA;
0.011mg/100mL; internal standard), EDTA (0.02mg/100mL), sodium metabisulfite
(0.1mg/100mL) in 6mM HCl] and then centrifuged at 12,000 xg for 10 minutes. The supernatant
samples were filtered through a 0.2 µm nylon disposable syringe filter and centrifuged rotovaped
to dryness (45°C and 0.1 bar; Centrivap Concentrator, Labconco, Kansas City, MO USA).
Samples were then reconstituted in 1000 µL of phosphate buffer (pH= 7.4) and stored at -80 °C
until analyzed by HPLC.
The neuroactive compounds were separated on a reverse-phase HPLC system with
electrochemical and UV detection configured in series. Separation was carried out on a 150 x
2.00 mm LUNA 5µm C18 column (Phenomenex, Torrence, CA USA) using an acetonitrile/
phosphate buffer with ion pairing agent mobile phase (MD-TM; Thermo Scientific) delivered at
a flow rate of 0.5 mL/min. Dual electrochemical detection (ESA Coulochem III; E1app= -150
mV; E2app= +300 mV; Thermo Scientific, Sunnyvale, CA USA ) and dual wavelength UV
detection ( λ1= 245nm; λ2= 280 nm; BioAnalytical Systems, West Lafayette, IN USA) were used
to quantify the compounds of interest using the internal standard calibration method.
Chromatographic data was collected, stored, and analyzed using EZ Chrom chromatography
software (Thermo Scientific). Protein content of tissue punches was determined by the Modified
Lowry Protein Assay (Pierce; Thermo Scientific, Sunnyvale, CA USA).
Statistical Analysis
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Differences in brain tissue levels of the biogenic amines were evaluated using a two-way
ANOVA with post-hoc comparisons (n=6-9 brains per diet group; GraphPad Prism 4.0,
GraphPad Software, Inc. San Diego, CA, USA).

Results
A three week KD regimen did not alter the tissue levels of NE, DA, 5HT, DOPAC, HVA,
or 5HIAA in any of the brain regions analyzed (Table 1). The KD did result in a brain regionspecific increase in the activity of DA neurons as measured by the metabolic ratio. Figure 1A
shows that mice fed a ketogenic diet had a significantly higher dopaminergic metabolic ratio (the
ratio of the tissue levels of the major dopamine metabolites, DOPAC and HVA, to the tissue
level of DA) in the motor cortex and somatosensory cortex regions (p<0.001 and p< 0.05,
respectively). In the motor cortex, the ratio increased 71% , from a value of 3.66 to a value of
6.27, over controls. In the somatosensory cortex the ratio increased 151%, from a value of 1.14
to a value of 2.86, over controls. An increase was also observed in the midbrain region of mice
fed a KD that approached significance (2.69 vs. 4.29; p=0.053). There was no difference in the
serotonin metabolic ratio ([5HIAA]/ [5HT]) between diet groups in any brain region sampled
(Figure 1B).

Discussion
Numerous studies utilizing animal models to study the effect of the KD have recently
been reported (see review [16]). However, little is known about the effects of the ketogenic diet
on the neurochemical content in brain regions in these models. In the present study, the steadystate tissue levels of the major monoamine neurotransmitters NE, DA, and 5-HT were not
changed in six different brain regions by a 3-week regimen of the low-fat, high-carbohydrate KD
(Table 1). Similar results have recently been reported showing no change in tissue dopamine
level in the striatum of mice fed a KD for 2 weeks [17]. Kynurenic acid, a metabolite of
tryptophan (serotonin precursor), was shown to be increased in the hippocampus and striatum but
not the cortex of rats fed a ketogenic diet for 21 days [11]. Similarly, in the present study, an
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increase in the dopaminergic metabolic ratio was shown to be altered in a region-specific manner
by the KD (Figure 1).
The dopaminergic system has been clearly identified as having seizure-modulating
effects [18]. This modulating effect is very brain region and dopamine receptor subtype specific.
It was recently reported that dopamine, acting through D1 receptors, decreased neuronal activity
in the rat cortex [19]. Local application of dopamine has been shown to inhibited spontaneous
firing rates in pyramidal tract neurons in the rodent motor cortex [20]. In the current study, the
ketogenic diet altered cortical dopamine activity as measured by an increase in the metabolite-totransmitter ratio. An increase in this ratio is generally accepted to be representative of an
increase in dopamine turnover produced by an increase in dopamine release. Increased
inhibition of cortical neuronal activity as a result of increased dopamine release presents a
possible mechanism for the KD's therapeutic effect. Using trans-cranial magnetic stimulation
(TMS), Cantello et al. [12] have reported an increase in inhibition, as determined by an
enhancement of measured intra-cortical inhibition (SICI), in the cerebral cortex of normal
humans fed a KD. Inhibition of cortical neurons by dopamine has been reported in humans[21].
In the present study, a significant increase in dopaminergic neuronal activity, as measured by the
metabolites-to-neurotransmitter ratio, was found in the motor and sensory cortex regions of mice
fed a KD for three weeks (Figure 1A). Thus, it can be proposed that the KD acts directly on
meso-cortical dopaminerigic neurons and that subsequent increased cortical inhibition via
increased meso-cortical DA activity may contribute to the anti-seizure properties of the KD.
Alternatively, the observed increase in cortical dopaminergic activity may have been
generated through an indirect pathway involving elevated adenosine and the glutamate-dopamine
synapse within the ventral tegmental area (VTA). Recently an increase in adenosine levels in
neuronal tissue and subsequent increase in A1 receptors has been proposed as a mechanism
responsible for altered cortical activity following a KD [7, 22]. Adenosine was shown to
selectively inhibit mGluR IPSPs in VTA dopamine neurons via A1 receptor antagonism [23].
The authors suggest that this would result in more effective burst firing, thereby resulting in an
increase in dopamine neuronal activity. The KD could therefore produce its therapeutic effect
through an increase in adenosine and subsequent stimulation of A1 receptors on glutamatergic
afferents which would result in the disinhibition of the VTA dopaminergic neurons.
Interestingly, the aspartate-glutamate homeostasis in cerebellar neurons was disrupted when β-
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hydroxybutarate was used as an energy source for the neurons, resulting in a decrease in
neuronal glutamate content [24]. This decrease in glutamate release as a result of the energysource change produced by the KD would also result in a disinhibition of the VTA dopaminergic
neurons and the observed increase in cortical dopaminergic metabolic ratio.
It is to be noted that the KD used in this study contained a significantly higher amount of
the antioxidant vitamin E (244 IU/kg compared to 42 IU/kg). Sharma and Nehru [25] recently
reported that rats administered vitamin E (100 IU/kg/day i.m.) for 35 days had increased levels
of dopamine in the midbrain. Future investigations to elucidate the mechanism responsible for
the therapeutic effect of the KD will have to include the impact of increased dietary antioxidants.
To our knowledge, the current report is the first to evaluate the effect of a chronic KD on
tissue levels of monoamine neurotransmitters in multiple brain regions of experimental animals.
While no change in the tissue content of neurotransmitters or metabolites was observed after
three weeks on the KD, the observed increase in the metabolic ratio for the dopaminergic system
within the motor and somatosensory cortex suggests involvement of the meso-cortical
dopaminergic system in the anti-convulsive effect of the KD. Evaluation of KD-induced cellular
metabolism changes and the above mentioned neurotransmitter systems within this localized
region may provide insight into the therapeutic differences seen between the KD and standard
anti-epileptic pharmacological treatments in humans.
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Table 1 – Neurochemical content from selected brain regions of mice fed either a normal chow
(Control) or a ketogenic diet (Ketogenic). Data are reported as ng/mg protein (S.E.M.) for n = 68 animals.
Brain
Structure

MC
SC
NA
ACPu
PCPu
MB

NE

DA

5HT

DOPAC

HVA

5HIAA

Control

Ketogenic

Control

Ketogenic

Control

Ketogenic

Control

Ketogenic

Control

Ketogenic

Control

Ketogenic

29.6
(4.1)
35.5
(9.4)
31.2
(8.5)
32.4
(11.1)
20.8
(4.3)
47.0
(81)

38.5
(10.4)
38.4
(9.4)
27.6
(3.6)
22.6
(42)
31.2
(8.2)
61.9
(8.3)

33.1
(9.3)
65.4
(10.6)
231.9
(31.5)
289.9
(54.6)
132.3
(16.8)
25.2
(5.1)

20.5
(9.6)
61.8
(24.5)
233.8
(48.7)
281.2
(45.4)
206.9
(63.8)
20.1
(4.3)

32.0
(5.4)
35.9
(7.1)
33.7
(5.5)
24.6
(7.8)
30.2
(5.9)
37.9
(7.7)

32.5
(4.4)
45.7
(12.7)
38.9
(7.5)
29.7
(6.5)
39.1
(8.3)
35.1
(7.6)

8.7
(2.1)
18.9
(5.0)
30.5
(4.8)
37.2
(7.4)
15.5
(4.3)
12.5
(2.1)

12.1
(3.8)
18.4
(5.5)
37.5
(8.7)
35.7
(9.1)
27.5
(4.4)
16.4
(3.5)

62.9
(7.8)
64.3
(7.7)
57.3
(12.1)
88.8
(21.9)
52.1
(11.8)
51.5
(8.1)

90.6
(30.7)
113.5
(38.0)
75.9
(14.1)
92.9
(27.4)
93.1
(18.5)
76.6
(13.9)

17.4
(3.0)
17.7
(3.9)
18.4
(4.0)
18.7
(5.5)
15.8
(4.0)
22.7
(3.5)

17.2
(5.6)
22.7
(6.9)
17.0
(3.8)
14.1
(2.6)
19.5
(4.1)
26.2
(4.0)

